Sorry, you need to enable JavaScript to visit this website.

    Pfizer Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation

    (BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has been notified of an unsolicited mini-tender offer by TRC Capital Corporation of Toronto (TRC) for TRC to purchase in cash up to four million shares, or approximately 0.057%, of the outstanding Pfizer common stock, at a price of $25.00 per share. TRCs offer price of $25.00 per Pfizer share represents a 2.31% discount to the closing price on June 26, 2007, the day before the commencement of TRCs unsolicited mini-tender offer, and a 3.55% discount to the closing price of $25.92 on Friday, July 6, 2007.

    Pfizer does not endorse TRCs unsolicited mini-tender offer and recommends that stockholders not tender their shares in response to this mini-tender offer. Pfizer is not in any way associated with TRC, this mini-tender offer or the offer documentation.

    Mini-tender offers, such as this one by TRC, do not give investors the same level of protection afforded by larger tender offers. For example, in making this offer, TRC is not required to file disclosure and other offer documents with the Securities and Exchange Commission (SEC) or adhere to additional procedures mandated by U.S. securities laws.

    Pfizer urges investors to:

    • Obtain current market quotes for their shares of common stock,
    • Consult with their financial advisors, and
    • Exercise caution with respect to TRCs offer.

    The SEC has issued Investor Tips on mini-tender offers, which note that often in making the offers at below-market prices, bidders are hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price. The SECs advisory is available at www.sec.gov/investor/pubs/minitend.htm.

    Pfizer encourages stockbrokers and dealers as well as other market participants to review the SECs and the New York Stock Exchanges (NYSE's) recommendations on the dissemination of mini-tender offers. These recommendations are available at www.sec.gov/divisions/marketreg/minitenders/sia072401.htm and in the Information Memo Number 01-27, issued by the NYSE on September 28, 2001, which can be found under the NYSE Regulation Rules & Interpretations Information Memos tab at www.nyse.com.

    Pfizer Inc
    Shreya Prudlo, 212-733-4889

    Sign up for the latest Pfizer Wire news alerts

    Receive real-time updates on Pfizer’s news delivered directly to your inbox.

    Our Pipeline: Potential Breakthroughs in the Making

    We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Media Asset Library

    Click here to view our media asset library.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.

    Stay up to date on the latest news and alerts through the Pfizer Wire

    Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. 

     

    Sign Up Now